These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 8611686)

  • 1. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome.
    Mauch PM; Kalish LA; Marcus KC; Coleman CN; Shulman LN; Krill E; Come S; Silver B; Canellos GP; Tarbell NJ
    Blood; 1996 May; 87(9):3625-32. PubMed ID: 8611686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.
    Mauch PM; Kalish LA; Marcus KC; Shulman LN; Krill E; Tarbell NJ; Silver B; Weinstein H; Come S; Canellos GP; Coleman CN
    Cancer J Sci Am; 1995; 1(1):33-42. PubMed ID: 9166452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
    van Leeuwen FE; Klokman WJ; Hagenbeek A; Noyon R; van den Belt-Dusebout AW; van Kerkhoff EH; van Heerde P; Somers R
    J Clin Oncol; 1994 Feb; 12(2):312-25. PubMed ID: 8113838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of second cancers in patients treated for Hodgkin's disease.
    Boivin JF; Hutchison GB; Zauber AG; Bernstein L; Davis FG; Michel RP; Zanke B; Tan CT; Fuller LM; Mauch P
    J Natl Cancer Inst; 1995 May; 87(10):732-41. PubMed ID: 7563150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment.
    Swerdlow AJ; Barber JA; Hudson GV; Cunningham D; Gupta RK; Hancock BW; Horwich A; Lister TA; Linch DC
    J Clin Oncol; 2000 Feb; 18(3):498-509. PubMed ID: 10653865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer after treatment of Hodgkin's disease.
    Hancock SL; Tucker MA; Hoppe RT
    J Natl Cancer Inst; 1993 Jan; 85(1):25-31. PubMed ID: 8416252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hodgkin's disease: study of treatment intensities and incidences of second malignancies.
    Rodriguez MA; Fuller LM; Zimmerman SO; Allen PK; Brown BW; Munsell MF; Hagemeister FB; McLaughlin P; Velasquez WS; Swan F
    Ann Oncol; 1993 Feb; 4(2):125-31. PubMed ID: 8448080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second malignancies after Hodgkin's disease: the Munich experience.
    Munker R; Grützner S; Hiller E; Aydemir U; Enne W; Dietzfelbinger H; Busch M; Haas R; Emmerich B; Schmidt M; Dühmke E; Hölzel D; Wilmanns W
    Ann Hematol; 1999 Dec; 78(12):544-54. PubMed ID: 10647878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.
    Salloum E; Doria R; Schubert W; Zelterman D; Holford T; Roberts KB; Farber LR; Kiehl RK; Cardinale J; Cooper DL
    J Clin Oncol; 1996 Sep; 14(9):2435-43. PubMed ID: 8823321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second cancers following pediatric Hodgkin's disease.
    Wolden SL; Lamborn KR; Cleary SF; Tate DJ; Donaldson SS
    J Clin Oncol; 1998 Feb; 16(2):536-44. PubMed ID: 9469338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of stage and treatment modality on the likelihood of second malignancies and hematopoietic disorders in Hodgkin's disease.
    Mendenhall NP; Shuster JJ; Million RR
    Radiother Oncol; 1989 Mar; 14(3):219-29. PubMed ID: 2710953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease.
    Beaty O; Hudson MM; Greenwald C; Luo X; Fang L; Wilimas JA; Thompson EI; Kun LE; Pratt CB
    J Clin Oncol; 1995 Mar; 13(3):603-9. PubMed ID: 7884422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second solid malignancies after combined modality therapy for Hodgkin's disease.
    Doria R; Holford T; Farber LR; Prosnitz LR; Cooper DL
    J Clin Oncol; 1995 Aug; 13(8):2016-22. PubMed ID: 7636543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hodgkin's disease: complications of therapy and excess mortality.
    Hoppe RT
    Ann Oncol; 1997; 8 Suppl 1():115-8. PubMed ID: 9187444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased mortality after successful treatment for Hodgkin's disease.
    Hudson MM; Poquette CA; Lee J; Greenwald CA; Shah A; Luo X; Thompson EI; Wilimas JA; Kun LE; Crist WM
    J Clin Oncol; 1998 Nov; 16(11):3592-600. PubMed ID: 9817280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time.
    Foss Abrahamsen A; Andersen A; Nome O; Jacobsen AB; Holte H; Foss Abrahamsen J; Kvaløy S
    Ann Oncol; 2002 Nov; 13(11):1786-91. PubMed ID: 12419752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease.
    Henry-Amar M
    Ann Oncol; 1992 Sep; 3 Suppl 4():117-28. PubMed ID: 1450072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation.
    Swerdlow AJ; Douglas AJ; Hudson GV; Hudson BV; Bennett MH; MacLennan KA
    BMJ; 1992 May; 304(6835):1137-43. PubMed ID: 1392790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age.
    Abrahamsen JF; Andersen A; Hannisdal E; Nome O; Abrahamsen AF; Kvaløy S; Høst H
    J Clin Oncol; 1993 Feb; 11(2):255-61. PubMed ID: 8426202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.